Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC Advertising "Tone-Down" Could Address FDA Concerns, Schering Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Marketers will begin airing more balanced DTC ads as a result of increased scrutiny from FDA about the quality of some ads, Schering CFO Bertolini says. With Levitra, Schering now participates in what may be a high-risk market for DTC ads: erectile dysfunction disorder.

You may also be interested in...

“Reminder Ads” May Be Backfiring On Industry, Pfizer Exec Says

“Reminder ads” are a disservice to consumers and physicians, Pfizer marketing exec Dahan says. Patients must “take two steps backward to go one step forward,” and doctors must field questions about drugs that aren’t relevant to the patient, creating a “negative stir” regarding direct-to-consumer ads.

FDA Acting Commissioner Crawford Touts Benefits Of DTC Advertising

Crawford emphasizes the need for industry self-regulation of direct-to-consumer promotion at Biotechnology Industry Organization/Windhover conference. The acting commissioner's remarks are softer than his recent calls for FDA enforcement action against "out of hand" DTC ads.

Schering, GSK Reviewing Levitra Promotions After FDA Cites 15-Second TV Ad

Commercial for Levitra does not qualify as "reminder ad" because it includes effectiveness claims, agency says in an ad division letter. Acting Commissioner Crawford has expressed a desire to crack down on DTC ads in the erectile dysfunction category. Levitra is one of four products cited by the agency in letters posted over a two-day period.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts